Pick a company that has either, in your view, been too unfocused or one that been so afraid to venture from its core business that it has missed clear opportunities for diversification (US Company only). In a short (2-3 page) memo addressed to
the CEO, and playing the role of a strategy consultant, address the issue of focus (too much, too little) and the costs or missed opportunities that you think have been a source of lost value. Advise the CEO on a better way to think about “sticking to his core or going for more.”
It is important not to overrun your page limit. This is an executive memo. Do not ask the CEO to indulge you; tell him/her precisely and efficiently what he or she needs to know.
It is very important to read the attachments I have provided for the memo.
Also, answer these questions and please feel free to use them as a reference answering the questions.
What is the logic behind a related diversification?
What are the risk factors that lead executives to justify them when the actual logic would otherwise fail?
Why do you think they often fail their shareholders?
What is the far more tenuous logic of an unrelated diversification?
Why are they even more often a financial failure?
What are the exceptions to that rule?
P.S. Work will be checked for plagiarism.
Order This Solution
49051 Millions developed by 10% and working benefit in 2009 was 15012 Millions that developed by 6%. Roche is contributed CHF. 9874 Millions on R&D in 2009. The free trade stream out 2009 was 8893 that was 79% more than 2008. The aggregate representative of Roche are 81507. Out of them 80115 are changeless. The Sales commitment is more from US that is 38% than West Europe that is 28%. Since pharmaceutical advertising exercises impact the endorsing conduct of specialists, it is of most extreme significance to basically dissect the cases made in the limited time material of the medications. The degree to which pharmaceutical organizations advance the benefits of their items and applicable clinical trails give to specialists are not examined in Pakistan. The consequences of the present logical examination demonstrate that untrustworthy and one-sided claims with respect to the pharmaceutical items are uncontrolled in Pakistan. These medication advancements impact the recommending conduct of the General Practitioners, Consultants in this manner representing one of the possibly significant reasons for outlandish solution. Roche Pakistan Ltd is a Member of IFPMA and PMA and take after their moral business rules to offer its items. Roche Paksitan Ltd is at sixth positioning in Pakistan Pharmaceutical Market and its yearly deal is Rs. 5.2 Billions out of 2009 in Pakistan.>GET ANSWER